Loading clinical trials...
Loading clinical trials...
A Phase II Study of the c-Met Inhibitor ARQ 197 in Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
Conditions
Interventions
Tivantinib
Diagnostic laboratory biomarker analysis
+2 more
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
November 1, 2011
Primary Completion Date
March 1, 2014
Completion Date
April 1, 2014
Last Updated
August 28, 2019
NCT04973605
NCT06138275
NCT05862012
NCT06285318
NCT07391657
NCT07284758
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions